Skip to main page content (VSports)
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2011 Feb 15;71(4):1418-30.
doi: 10.1158/0008-5472.CAN-10-1728. Epub 2010 Dec 15.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth

Denis Drygin  1 , Amy Lin, Josh Bliesath, Caroline B Ho, Sean E O'Brien, Chris Proffitt, Mayuko Omori, Mustapha Haddach, Michael K Schwaebe, Adam Siddiqui-Jain, Nicole Streiner, Jaclyn E Quin, Elaine Sanij, Megan J Bywater, Ross D Hannan, David Ryckman, Kenna Anderes, William G Rice
Affiliations

"VSports最新版本" Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth

Denis Drygin et al. Cancer Res. .

Abstract

Deregulated ribosomal RNA synthesis is associated with uncontrolled cancer cell proliferation. RNA polymerase (Pol) I, the multiprotein complex that synthesizes rRNA, is activated widely in cancer. Thus, selective inhibitors of Pol I may offer a general therapeutic strategy to block cancer cell proliferation VSports手机版. Coupling medicinal chemistry efforts to tandem cell- and molecular-based screening led to the design of CX-5461, a potent small-molecule inhibitor of rRNA synthesis in cancer cells. CX-5461 selectively inhibits Pol I-driven transcription relative to Pol II-driven transcription, DNA replication, and protein translation. Molecular studies demonstrate that CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines. CX-5461 is orally bioavailable and demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models. Our findings position CX-5461 for investigational clinical trials as a potent, selective, and orally administered agent for cancer treatment. .

PubMed Disclaimer

Publication types

MeSH terms